

0040-4039(95)02396-8

Synthesis and Hybridization Properties of an Oligonucleotide Analog Containing a Glucose-derived Conformation-restricted Ribose Moiety and 2', 5' Formacetal Linkages

Ruiming Zou and Mark D. Matteucci*


Gilead Sciences, Inc., 353 Lakeside Drive, Foster City, CA, 94404, U.S.A.

Abstract: A pyrimidine trinucleoside containing a conformationally restricted ribose moiety and two 2', 5' formacetal internucleoside linkages was synthesized. The bicyclic ribose moiety was identified by molecular modeling as a candidate to preorder a nucleoside to resemble the bound duplex conformation. The thymine nucleoside analog was simply synthesized from glucose. The trimer was incorporated at the 3' end of a larger unmodified ON. The hybridization affinity of this chimeric ON analog to a complementary RNA was found to be somewhat inferior relative to a non conformationally restricted control.

Covalent conformational restriction of unbound ligands to resemble their bound state is a proven method for the enhancement of ligand-receptor interactions.¹ This concept is now beginning to be applied toward the enhanced recognition of nucleic acid receptors such as complementary RNA and DNA by oligonucleotides (ONs) ligands.² We have previously reported the synthesis and binding properties of ON analogs containing 3', 5' formacetal³ and 2', 5' formacetal internucleoside⁴ linkages. These modifications replace the phosphodiester with a small, non-ionic and non-chiral linkage and confer to the ON analogs comparable binding affinity for ssRNA. In an effort to improve the binding affinity of 2', 5' formacetal ON analogs, a conformation-restricted furanose moiety was simply synthesized in order to pre-order the ribose conformation. The common sugar, glucose, was converted into a 5,5 bicyclic ring system which locks the ribose torsion angles of the nucleoside into a conformation resembling the bound form of canonical A form duplex.⁵ We report the synthesis of the trinucleoside analog (**9**) (Scheme 1) bearing a 3', 6'-anhydro-glucose derivative, its incorporation into a longer ON, and the hybridization property of the ON analog with a complementary ssRNA sequence.

The synthesis of the trinucleoside **9** is outlined in Scheme 1. Treatment of 1, 2-*O*-isopropylidene- α -D-glucopyranose (**1**) with $\text{PhC(OMe)}_3/\text{TsOH}$ resulted in the formation of a glucose ortho ester intermediate, which underwent concomitant acid-catalyzed rearrangement to give the 3, 6-anhydroglucose derivative (**2**) in 98% yield.⁶ Acetolysis of **2** followed by glycosylation with silylated thymine in the presence of trimethylsilyltriflate (TMSOTf) furnished the desired nucleoside **3**. Selective removal of the 2'-*O*-acetyl protecting group of **3** was achieved with NaOMe/THF and subsequent treatment with $\text{Me}_2\text{S}/\text{Bz}_2\text{O}_2$ afforded the methylthiomethyl ether **4**.⁷ The 5'-*O*-benzoyl group of **4** was removed and replaced by a phenoxyacetyl (Pac) group to enable its facile, mildly basic, selective removal during the chain elongation process. The 2'-*O*-methylthiomethyl group **5** was then converted to the 2'-*O*-methyl diphenylphosphinate (**5**).^{7,8} Condensation of **5** with 2'-deoxy-N⁴-benzoyl-3'-*O*-t-butylidiphenylsilyl-5-methylcytidine (**6**)¹⁰ followed by

SCHEME 1



A: $\text{Ph}(\text{COMe})_3$, TsOH, CH_2Cl_2 , RT; B: AcOH, Ac_2O , H_2SO_4 , RT; C: thymine, BSA, MeCN, TMSOTf, 70°C ; D: NaOMe, THF, RT; E: Me_2S , Bz_2O_2 , MeCN, 0°C ; F: NaOMe, MeOH, RT; G: PacCl, Pyr, CH_2Cl_2 , RT; H: NIS, $\text{Ph}_2\text{PO}_2\text{H}$, DCE, RT; I: TMSOTf, MeCN, DCE, -40°C ; J: NH_3/MeOH , 0°C ; K: DMTCl, Pyr, CH_2Cl_2 , RT; L: TBAF, THF, RT; M: succinic anhydride, Et_3N , DMAP, DCE; N: TEAB; O: Pyr, DMF, diisopropylcarbodiimide

selective deprotection of the 5'-*O*-Pac group with NH₃/MeOH provided the dinucleoside **7**. Further chain elongation with the diphenylphosphinate **8**,¹¹ replacement of the 5'-*O*-Pac with a dimethoxytrityl (DMT) group, and desilylation at the 3' end gave the target trinucleoside **9**. The trinucleoside **9** was functionalized at the 3' end as a succinate and then coupled onto the controlled pore glass (CPG, amino form). This CPG was used for the solid phase ON synthesis using the H-phosphonate method.¹²

The trinucleoside **9** was incorporated into an ON of the sequence 5'-C^MTTC^MATTTTT^gT^gC^M-3', where C^M = 5-methyl-2'-deoxycytidine and T^gT^gC^M is **9**, the modified trinucleoside bearing two 2', 5' formacetal linkages and a conformation-restricted glucose monomer. The ONs of the same sequence, 5'-C^MTTC^MATTTTT^TC^M-3' (where T^TC^M is the non-conformationally restricted 2', 5' formacetal-linked trimer and all other linkages are 3',5' phosphodiester) and 5'-C^MTTC^MATTTTTTC^M-3' (all linkages are 3',5' phosphodiester) were also synthesized as controls in the hybridization experiments. The formation of the duplex between these ON analogs and the complementary ssRNA target (5'-GAAGAAAAAUGAAGAAAAU-3') was studied by thermal denaturation experiments using intracellular salt conditions.¹³

The T_m results are listed in Table 1. The T_m of the ON bearing two 2', 5' formacetal linkages was 2.5°C lower (-1.25°C/substitution) than that of the corresponding 3', 5' phosphate. This result was consistent with the previous observation from another 2', 5' formacetal ON (-0.5°C/substitution)⁴. Further modification by restriction of the sugar conformation with a 3', 6'-anhydroglucose moiety resulted in a destabilization (-0.75°C/substitution) of the duplex with the target ssRNA compared to the 2', 5' formacetal control.

ONs have potential application as antisense inhibitors.¹⁴ Formacetal linkages are of interest due to their lack of sensitivity to nucleases and their potential of favorable cellular permeation properties.^{3c} This particular attempt at covalent conformational restriction of the ribose moiety in conjunction with a 2',5' formacetal linkage has resulted in somewhat poorer binding affinity. A 5,5 bicyclic ring system is very rigid and causes a clear distortion of the sugar pucker geometries of the parent ribose ring.^{2a,2b} The hybridization properties of these ONs may be improved if the extreme rigidity of the 5,5 ring system is relaxed by creating a larger ring fused to the ribose. Work on the synthesis of 2', 5' formacetal ONs bearing such conformation-restricted sugar moieties is currently in progress.

Table 1. T_m Results

ON	Modification	T _m °C
5'-C ^M TTC ^M ATTTTTTC ^M -3'	3', 5' Phosphate	41.0
5'-C ^M TTC ^M ATTTTT ^T C ^M -3'	3'-Deoxyribo-2', 5' formacetal	38.5
5'-C ^M TTC ^M ATTTTT ^g T ^g C ^M -3'	3', 6'-Anhydrogluco-2', 5' formacetal	37.0

Acknowledgments: We thank Terry Terhorst for the solid phase ON synthesis, Theresa Huang for T_m measurements and Mary Hogsett for manuscript preparation.

REFERENCES AND NOTES:

1. a) Cram, D.J. *Angew. Chem., Int. Ed. Engl.* **1988**, *27*, 1009.
b) Lehn, J.-M. *Angew. Chem., Int. Ed. Engl.* **1988**, *27*, 89.
c) Hirschmann, R. *Angew. Chem., Int. Ed. Engl.* **1991**, *30*, 1278.
2. a) Tarkov, M.; Bolli, M.; Schweizer, B.; Leumann, C. *Helv. Chim. Acta* **1993**, *76*, 481.
b) Jones, R.J.; Swaminathan, S.; Milligan, J.F.; Wadwani, S.; Froehler, B.C.; Matteucci, M.D. *J. Am. Chem. Soc.* **1993**, *115*, 9816.
c) Tarkov, M.; Bolli, M.; Leumann, C. *Helv. Chim. Acta* **1994**, *77*, 716.
3. a) Matteucci, M.D. *Tetrahedron Lett.* **1990**, *31*, 2385.
b) Veeneman, G.H.; van der Marel, G.A.; van den Elst, H.; van Boom, J.H. *Tetrahedron* **1991**, *47*, 1547.
c) Jones, R.J.; Lin, K.-Y.; Milligan, J.F.; Wadwani, S.; Matteucci, M.D., *J. Org. Chem.* **1993**, *58*, 2983.
4. Pudlo, J.S.; Cao, X.; Swaminathan, S.; Matteucci, M.D. *Tetrahedron Lett.* **1994**, *35*, 9315.
5. Modeling studies performed using Biograf software from Molecular Simulations Inc. The principle conformational restriction within this analog is the freezing of rotation about the C5'-O5' bond thereby fixing a gauche relationship between the O4' and O5'. The ribose ring pucker is likely locked in a 3' endo (A helix like) conformation by the 2' oxygen substituent.
6. Compound **2** had been prepared previously from 1, 2, 5, 6-diisopropylidene-D-glucose via a four-step synthesis (Ernie Prisbe, personal communication).
7. Quaedflieg, P.J.L.M.; Timmers, C.M.; van der Marel, G.A.; Kuyl-Yeheskiely, E.; van Boom, J.H. *Synthesis* **1993**, 627.
8. The dibutyl phosphate acetals⁷ have been found to be unstable; a stable variant is the diphenylphosphinate.⁹
9. Zhang, L.; Matteucci, M.D. *Tetrahedron Lett.*, submitted.
10. Divaker, K.L.; Reese, C.B. *J. Chem. Soc. Perkin Trans.* **1982**, *1*, 1171.
11. The diphenylphosphinate **8** was prepared from 1-(2-O-methylthiomethyl-5-O-toluoyl-3-deoxy-β-D-ribofuranosyl)thymine⁴ by the replacement of the 5'-O-toluoyl with a phenoxyacetyl group and subsequent treatment with Ph₂POOH/NIS.⁹
12. Froehler, B.C.; Ng, P.G.; Matteucci, M.D. *Nucl. Acids Res.* **1986**, *14*, 5399.
13. The concentration of all ONs was 2.8 μM, and the following buffer was used: 140 mM KCl, 5mM Na₂HPO₄ (10 mM Na⁺), 1 mM MgCl₂ and pH 7.2. These salt conditions were chosen to approximate the intracellular cationic environment. See: Alberts, B.; et al. *Molecular Biology of the Cell*; Garland: New York, 1989: p. 301.
14. a) Uhlmann, E.; Peymen, A. *Chem. Rev.* **1990**, *90*, 543.
b) Milligan, J.F.; Matteucci, M.D.; Martin, J.C. *J. Med. Chem.* **1993**, *36*, 1923.

(Received in USA 16 October 1995; accepted 1 December 1995)